Table of Contents
- regulatory developments affecting our current or future product candidates;
- our execution of any collaborative, licensing or similar
arrangements and the timing of payments we may make or receive
under these arrangements; and
- nature and terms of stock-based compensation grants and any intellectual property infringement lawsuit in which we may
our quarterly operating results fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially. Furthermore, any quarterly
fluctuations in our operating results may, in turn, cause the price of our stock to fluctuate substantially.
If securities or industry analysts do not publish research or reports or publish unfavorable research or reports about our business, our stock price and trading volume could
The trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish
about us, our business, our market or our competitors. We do not currently have and may never obtain research coverage by securities and industry analysts. If no securities or industry analysts
commence coverage of our company, the trading price for our stock would be negatively impacted. In the event we obtain securities or industry analyst coverage, if one or more of the analysts who
covers us downgrades our stock, our stock price would likely decline. If one or more of these analysts ceases to cover us or fails to regularly publish reports on us, interest in our stock could
decrease, which could cause our stock price or trading volume to decline.
We may use the net proceeds from this offering in ways that you and other stockholders may not approve.
Our management will have broad discretion in the application of the net proceeds from this offering, including for any of the purposes
described in the section entitled "Use of Proceeds," and you will not have the opportunity as part of your investment decision to assess whether the net proceeds are being used appropriately. Because
of the number and variability of factors that will determine our use of the net proceeds from this offering, their ultimate use may vary substantially from their currently intended use. Our management
might not apply our net proceeds in ways that ultimately increase the value of your investment. We intend to use the net proceeds from this offering, together with our existing cash resources to fund
the continued development of VTP-43742, VTP-38443 and VTP-38543, to fund our continued discovery efforts to identify additional drug candidates for new therapeutic molecular targets, including our
immuno-oncology program and for working capital, debt maintenance and general corporate purposes. The failure by our management to apply the net proceeds from this offering effectively could harm our
business. Pending their use, we may invest the net proceeds from this offering in a variety of capital preservation investments, including short-term, interest-bearing, investment-grade instruments
and U.S. government securities. These investments may not yield a favorable return to our stockholders.
You will suffer immediate and substantial dilution in the net tangible book value of the common stock you purchase.
The initial public offering price of our common stock is substantially higher than the pro forma as adjusted net tangible book value
per share of our outstanding common stock immediately after the completion of this offering. Purchasers of common stock in this offering will experience immediate dilution of approximately
$ per share, assuming an initial public offering price of $ per share, the midpoint of the range set forth
on the cover of this prospectus. In the past, we issued options
and warrants to acquire common stock at prices significantly below the initial public offering price. To the extent these outstanding options and warrants are ultimately exercised, investors
purchasing common stock in this offering will sustain further dilution. For a further description of the dilution that you will experience immediately after this offering, see "Dilution."